1. A vaccine composition comprising at least one norovirus VLP antigen and at least one rotavirus VP6.2 antigen. The vaccine composition of claim 1, further comprising a norovirus antigen selected from the group consisting of capsid antigenic peptides and capsid antigenic proteins. The vaccine composition according to claim 1, wherein said norovirus antigen is obtained from the group consisting of noroviruses GI and GII and their genotypes. The vaccine composition according to claim 3, where the specified norovirus antigen is a VLP GII-4.5. The vaccine composition of claim 4, wherein said VLP GII-4 is monovalent. The vaccine composition of claim 1, wherein said norovirus antigen comprises more than one type of VLP. The vaccine composition according to claim 1, wherein said rotavirus VP6 antigen is selected from the group consisting of rVP6 protein, bilayer VLP VP2 / VP6, VLP containing VP6 protein, and any combination thereof. The vaccine composition of claim 7, wherein said rVP6 is in multimeric form selected from the group consisting of tubes, spheres, sheets, and any combination thereof. A vaccine composition according to claim 1, further comprising a sterile non-toxic pharmaceutically acceptable physiological carrier. A vaccine composition according to any one of claims 1 to 9 for use in the prophylaxis of a disease selected from the group consisting of norovirus and rotavirus infection, diarrhea and vomiting caused by viruses, and gastroenteritis. 11. A method of producing a vaccine composition according to any one of claims 1 to 8, comprising co-expression of at least one norovirus VLP and at least one rotavirus VP6 antigen in one host or comprising the steps of a) obtaining, isolating and purifying at least one norovirus VLP antigen ； b) the floor1. Композиция вакцины, включающая по меньшей мере один антиген норовирусной VLP и по меньшей мере один антиген ротавирусного VP6.2. Композиция вакцины по п.1, дополнительно содержащая норовирусный антиген, выбранный
